• Autonomix Medical received U.S. Patent No. 12,544,131 covering transvascular monitoring and treatment systems that validate nerve-targeted procedures in real time using electrophysiological signals.
• The patent covers catheter-based tools that operate inside a vessel, with deployable probes designed to access tissue or nerves beyond the vessel wall.
• It also includes claims for multi-site sensing to improve signal quality, procedural-completion assessment, and closed-loop control that adjusts therapy based on live feedback.
• The award expands the company’s intellectual property position around its neuromodulation platform, with potential use across multiple nerve-targeted indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190830PRIMZONEFULLFEED9722649) on May 19, 2026, and is solely responsible for the information contained therein.